Indivior plc
http://indivior.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Indivior plc
FTC Commissioner Changes Could Impact Pharma Mergers, Scrutiny Of Biosimilars Uptake
President Biden’s picks to fill two commissioner posts may shift dynamics on pharmaceutical industry enforcement. Rohit Chopra’s nomination to Consumer Financial Protection Bureau removes strong critic of pharma mergers.
Teva Has A New Near-Term Opportunity With Subcutaneous Risperidone
A Phase III trial for an extended-release subcutaneously administered version of the antipsychotic risperidone was positive in patients with schizophrenia.
House Bills Would Close Orphan Exclusivity ‘Loophole’ And Thaw ‘Frozen’ Generic Labeling
US FDA-related legislation among the bills moving during the lame duck session of Congress.
Indivior Reorganizing And Re-Investing In US Commercial Functions
Indivior aims to cut costs by restructuring its US commercial operations and reducing discretionary spending, in order to improve flexibility in the face of the COVID-19 pandemic and to invest in R&D.
Company Information
- Industry
-
Pharmaceuticals
- Drug Delivery
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Indivior Inc.
- Indivior UK Limited
- Reckitt Benckiser Pharmaceuticals Inc. (RBP)